Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on May 06, 2014 1:01pm

181 Views

Post# 22529690

RE:nature article

Hi Testy:

Thank you for your post. I went looking for that article yesterday as a matter of fact. My local newstand had "Nature" in stock, but it was already the May issue. The article in question is from the prior issue (April) and they did not have that one unfortunately.

I might try and see if a local branch library has it. If I get my hands on it, I'll let folks know but no promises as my schedule is a bit busy right now....

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX